Premium content

Clinical trial planned for new cognitive impairment drug

Published

1 month ago

24 October 2023

Clinical stage pharma company PharmaKure is set to embark on a clinical trial of a combined drug for patients with mild cognitive impairment.

PharmaKure has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare Regulatory Agency (MHRA) in the United Kingdom to evaluate PK051.

Unlock this article and more exclusive content every day as an NR Times subscriber. Just £24.99 / $30 / €28 per year.

Up Next

‘Make care an attractive career option’

Don't Miss

Interview: Prof Rudi Coetzer on the neuro-behavioural approach to rehab

Brain injury4 weeks ago

How I got my cockiness back

Tech4 weeks ago

Clever design, innovation and craftsmanship deliver an outstanding solution for the Edwards family

Case management3 weeks ago

Making client dreams come true

News4 days ago

Compassion focused therapy: Lessons from the frontline of brain injury care

Premium content4 weeks ago

Concussion in sports: new innovations poised to transform the landscape

Inpatient rehab2 weeks ago

Introducing Chislehurst

Professional Insight3 weeks ago

Dealing with ambiguous loss

Tech4 weeks ago

Introducing the MetaMotus Galileo

Cookie	Duration	Description
__cfduid	1 month	The cookie is used by cdn services like CloudFare to identify individual clients behind a shared IP address and apply security settings on a per-client basis. It does not correspond to any user ID in the web application and does not store any personally identifiable information.
_GRECAPTCHA	5 months 27 days	This cookie is set by Google. In addition to certain standard Google cookies, reCAPTCHA sets a necessary cookie (_GRECAPTCHA) when executed for the purpose of providing its risk analysis.
cookielawinfo-checkbox-advertisement		The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".
cookielawinfo-checkbox-analytics		This cookies is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".

Cookie	Duration	Description
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.
iutk	5 months 27 days	This cookie is used by Issuu analytic system. The cookies is used to gather information regarding visitor activity on Issuu products.

Cookie	Duration	Description
cookielawinfo-checkbox-functional	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-others		No description
lfuuid	9 years 11 months	Third party (Lead Forensics) cookie which enables us to track visitor behaviour on our site. Tracking is performed anonymously until a user identifies themselves by submitting a form.
S	1 hour	No description

Neuro Rehab Times

Clinical trial planned for new cognitive impairment drug

Premium content

Clinical trial planned for new cognitive impairment drug

Unlock this article and more exclusive content every day as an NR Times subscriber. Just £24.99 / $30 / €28 per year.

Trending

Neuro Rehab Times

Clinical trial planned for new cognitive impairment drug

Unlock this article and more exclusive content every day as an NR Times subscriber. Just £24.99 / $30 / €28 per year.

You may like

Trending